Drugs Affecting Coaguation Flashcards

1
Q

What is the difference between haemostasis and coagulation?

A

Haemostasis: Arrest of blood loss from damaged vessels
Coagulation: Formation of a fibrin clot in a blood vessel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the difference between an arterial and venous thrombus?

A

Thrombus: Forms in vivo

Arterial thrombus (white):

- Platelets plus white blood cells in a fibrin mesh 
- Usually associated with vessel wall damage (atherosclerosis) 
- Breaks off leading to blood vessel obstruction (eg myocardial infarction) 

Venous thrombus (red):

- Fibrin, platelets and red blood cell
- Usually associated with blood stasis (eg DVT with air travel) 
-   Breaks off leading to embolus lodging in lungs or brain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Explain the terms:

Thrombosis

Thromboembolis

Clot

A

Thrombosis: Pathological formation of a haemostatic plug in a blood vessel in the absence of blood loss

Thromboembolus: A blockage in a blood vessel caused by a dislodged thrombus

Clot: Forms in static blood in vitro

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Explain how damage to a blood vessel can cause vasoconstriction?

A

Mechanism:

- Collagen exposed on damaged vessel wall 
- Platelets stick to collagen and “activate” 
- ADP and 5-HT released from platelets 
-  5-HT is a powerful vasoconstrictor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Explain how damage to a blood vessel can cause platelet adhesion and activation (thrombus formation)?

A

Mechanism:

- ADP from activated platelets causes others to 	activate and change shape 
- Granule contents are secreted (eg ADP, 5-HT) 
- Mediators are synthesised (eg Thromboxane) 
- Platelets aggregate and adhere via fibrinogen 	bridging between GPIIb/IIIa receptors 
- Soft plug formed

Stimuli for Platelet Activation: 

- Collagen 
- Thrombin 
- Thromboxane 
- ADP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Explain how damage to a blood vessel can cause fibrin formation (thrombus formation)?

A

Mechanism:

- Fibrin is formed from fibrinogen (a soluble plasma protein) 
- Thrombin cleaves fibrinogen--> fibrin (insoluble monomers) 
- Thrombin is not present in plasma: is produced by activation of prothrombin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How is prothrombin activated?

A
  • A “cascade” reaction where inactive precursors are activated in series- each giving rise to more of the next
  • Two pathways in the cascade:
    – Extrinsic- in vivo: damaged tissues release thromboplastin
    – Intrinsic- in vitro: exposed collagen or other material, negative charges (eg glass)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Explain the coagulation cascade?

A
  • A small signal (eg FXII) leads to a large amount of product (fibrin)
  • Each step leads to formation of more product ie amplification
  • The ‘factors’ are proteases
  • The extrinsic pathway is faster than intrinsic pathway (that has many more steps)
  • Each step leads to more product - AMPLIFICATION
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How is blood coagulation controlled?

A
  • Control is inhibited by:
    • Enzyme inhibitors (ie/ antithrombin III–> cascade inhibition)
    • Fibrinolysis by plasmin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Why do coagulation drugs work?

A

Drugs that are used affect haemostasis and thrombosis because:
- Some situations of blood stasis leading to thrombus formation:
- Atrial fibrillation
-> cerebral embolism or -> renal embolism
- Deep vein thrombosis (DVT)
–  Pulmonary embolism
- Some situations of blood vessel damage leading to thrombus formation:
- atherosclerosis
–  In coronary vessels–> myocardial infarction
–  In carotid arteries –> stroke

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What processes can coagulation drugs affect?

A
  • coagulation (fibrin formation)
  • platelets
    –  adhesion and activation
  • fibrinolysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Explain some drugs that affect Fibrin formation.

A
  • Procoagulant drugs eg vitamin K
    Vitamin K:
    • Essential for formation of clotting factors II, VII, IX, and X
    • These molecules all require gamma carboxylation after synthesis
    • Reduced vitamin K is a cofactor in carboxylation of glutamate
  • Injectable anticoagulants eg heparin, low-molecular-weight heparins
    – Used acutely for short term action

Heparin:
- Enhances activity of antithrombin III
- AT III is a natural inhibitor that inactivates Xa and thrombin
- Heparin binds AT III to expose active site
- LMW heparins:
–  have same effect on factor Xa, less effect on thrombin
–  Anticoagulant effects are similar
–  Large negatively charged (MW 60-100kD)
–  Not orally available
Low Molecular Weight Haparin (MW 2-9kD)
–  Not orally available
–  Longer elimination half life
–  Used for patient self administration @ home
- Averse Effects:
- Haemorrhage
- Thrombocytopaenia (platelet deficiency)
- Osteoporosis (mechanism unknown)

  • Oral anticoagulants eg warfarin
    – Used for prolonged therapy
    – Coumarin derivatives eg warfarin
    – Inhibit reduction of vitamin K, thereby inhibiting gamma carboxylation of glutamate in factors II, VII, IX and X
	Warfarin:
	- Only active in vivo 
	- Delayed onset of action 
	- Doesn’t affect already active factors
	- Adverse Effects:
		- haemorrhage 
			–  titrate dose 
			–  dosage determined by INR 
		- reversal 
			–  vitamin K (oral) 
			–  phytomenadione natural vitamin K (i.v.)
			–  fresh frozen plasma	
	- the moody drug (Warfarin levels and anticoagulant level effects are very labile)
	- Pharmacokinetics:
		- orally active  
		- rapidly absorbed  
		- strongly bound to plasma protein (99%)
  • Increased Warfarin activity:
    - vitamin K deficiency
    - hepatic disease –  impaired synthesis of clotting factors
    - hypermetabolic states –  increased metabolism of clotting factors
    - drug interactions
    - impaired platelet aggregation eg aspirin
    - competition for plasma protein binding eg NSAIDs
    -  Competition for Cytochrome p450 pathway so reduced warfarin clearance- increased availability
    - cimetidine ( a H2 receptor blocker- gastric ulcer treatment)
    - Acute alcohol consumption
  • Decreased Warfarin activity:
    - pregnancy
    - drug interactions
    – induction of liver enzymes eg barbiturates, chronic alcohol consumption increases warfarin clearance
    –  vitamin K supplements
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the monitoring effect?

A

Prothrombin Time (PT) – time for clot formation of plasma after addition of Ca2+ and tissue factor – extrinsic pathway

International Normalised Ratio (INR) – ratio of patient PT to normal PT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are some new anticoagulant agents?

A
  • Low molecular weight
  • Orally available
  • More predictable dose-response
  • Reduced laboratory monitoring
  • Indirect Factor Xa (FXa) inhibitors
  • Direct Factor Xa inhibitors
  • Direct Thrombin Inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are some Drugs that Affect Platelet Activation and Adhesion?

A
  • ADP receptor antagonists (eg clopidogrel)
  • Thromboxane synthesis inhibitors (cyclo-oxygenase inhibitors eg aspirin)
  • Glycoprotein IIb/IIIa receptor antagonists (eg tirofiban, abciximab)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the guidelines for use of platelet inhibitors?

A
  • As adjunctive therapy with aspirin
  • In patients intolerant to aspirin
    (Eg post ischaemic heart disease, atrial fibrillation (stroke prevention))
17
Q

What is the mechanism of such drugs as aspirin?

A
  • Aspirin stops platelet activation by inhibiting the enzyme cyclo-oxygenase 1. - This prevents the synthesis of thromboxane A2 which normally causes platelet aggregation.
  • Clopidogrel inhibits the activation of the glycoprotein IIb/IIIa complex by preventing adenosine diphosphate binding to a platelet receptor.
  • This inhibits platelet aggregation. Antagonists of the glycoprotein IIb/IIIa receptor stop platelet aggregation by blocking the binding of fibrinogen to the receptor.
  • Dipyridamole increases the production of prostacyclin, a potent inhibitor of platelet aggregation.
18
Q

Explain features of drugs that are Thromboxane (TXA2) Synthesis Inhibitors.

A
  • Thromboxane potent activator of platelets
  • Synthesized in platelets from arachidonic acid (membrane fatty acid)
  • Reaction catalyzed by cyclooxygenase
19
Q

What are some specific features of aspirin?

A
  • irreversible cyclo-oxygenase inhibitor
  • Reduced thromboxane synthesis
  • Decreased platelet aggregation
  • Decreased vasoconstriction
    Low Dose Aspiring Therapy:
  • Reduced thromboxane synthesis from platelets in portal vein
    –>Decreased platelet aggregation
    –>Decreased vasoconstriction
    AND
  • Retained prostaglandin I2 (PGI2) from endothelium
    –>Inhibition of platelet aggregation
    –>Promotion of vasodilation
20
Q

What are some other specific anti-platelet drugs?

A
  • GPIIb/IIIa receptor antagonist (eg Abciximab)
    –  Monoclonal antibody to GPIIb/IIIa
    –  For I/V use in high risk acute coronary syndromes
  • ADP receptor antagonists ( eg clopidigrel)
    –  Prevent binding of ADP to its receptor on platelets
    –  Thereby prevent platelet activation
    –  Given orally as prodrug
21
Q

What is fibrinolysis?

A

Control of blood coagulation is by:

- Enzyme inhibitors eg antithrombin III 
-  fibrinolysis
22
Q

What are some fibrolytic drugs?

A

Streptokinase:
–  Activates plasminogen
–  Used intravenously
–  Antigenic so single use
Alteplase
–  Human recombinant tissue plasminogen activators (hrtPA)
–  Not antigenic so can be given in patients that have received streptokinase
–  Short half life so I/V infusion
–  More active on fibrin bound plasminogen so “CLOT SELECTIVE”
–  Very expensive